CD274 and non-small cell lung carcinoma: Multiple studies have indicated that high non-synonymous mutation burden in non-small cell lung cancer (NSCLC) correlates to a better objective response and progression-free survival rate in anti-PD-1/PD-L1 therapy [16,17].